Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Share Price |
Shares Traded |
Shares Owned |
Own chg |
Value Traded |
1d ret |
1w ret |
1m ret |
6m ret |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2018-06-21 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $4.54 | +30,000 | 191,369,606 | 0% | +$136,200 | ||||||
| M | 2018-06-20 | ALRN | Aileron Therapeutics Inc | Apple Tree Partners II LP | 10% | S - Sale | $5.30 | -6,647 | 1,486,498 | 0% | -$35,233 | |||||
| DM | 2018-06-19 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $47.56 | -30,000 | 30,000 | -50% | -$1,426,745 | |||||
| DM | 2018-06-19 | PAHC | Phibro Animal Health Corp | Bfi Co., LLC | 10% | S - Sale+OE | $47.56 | -30,000 | 30,000 | -50% | -$1,426,745 | |||||
| M | 2018-06-19 | LXRX | Lexicon Pharmaceuticals, Inc. | Invus Public Equities, L.P. | Dir, 10% | P - Purchase | $13.29 | +72,973 | 59,804,301 | 0% | +$970,045 | |||||
2018-06-21 | RARE | Ultragenyx Pharmaceutical Inc. | Parschauer Karah Herdman | EVP, GC | S - Sale | $82.77 | -1,226 | 14,181 | -8% | -$101,476 | ||||||
| D | 2018-06-19 | LOXO | Loxo Oncology, Inc. | Burstein Jennifer | SVP of Finance | S - Sale+OE | $176.99 | -1,700 | 0 | -100% | -$300,888 | |||||
| DM | 2018-06-19 | LOXO | Loxo Oncology, Inc. | Van Naarden Jacob | Chief Business Officer | S - Sale+OE | $178.14 | -3,082 | 12,000 | -20% | -$549,036 | |||||
| DM | 2018-06-19 | LOXO | Loxo Oncology, Inc. | Bilenker Joshua H. | Pres, CEO | S - Sale+OE | $178.62 | -57,000 | 163,707 | -26% | -$10,181,356 | |||||
| D | 2018-06-19 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | EVP Research Pharma Ops, Tech | S - Sale+OE | $48.31 | -20,000 | 22,279 | -47% | -$966,240 | |||||
| D | 2018-06-20 | ARRY | Array Biopharma Inc | Van Lunsen Gil J | Dir | S - Sale+OE | $19.08 | -21,500 | 19,297 | -53% | -$410,220 | |||||
| D | 2018-06-19 | ARRY | Array Biopharma Inc | Sandor Victor | Chief Medical Officer | S - Sale+OE | $18.76 | -77,576 | 210,086 | -27% | -$1,455,326 | |||||
| DM | 2018-06-19 | GALT | Galectin Therapeutics Inc | Callicutt Jack W | CFO | S - Sale+OE | $8.61 | -226,000 | 1,260 | -99% | -$1,946,021 | |||||
| M | 2018-06-19 | SYBX | Synlogic, Inc. | Miller Paul Francis | Chief Scientific Officer | S - Sale | $9.77 | -3,000 | 72,135 | -4% | -$29,303 | |||||
| D | 2018-06-20 | CTLT | Catalent, Inc. | Fasman Steven L | SVP, GC | S - Sale+OE | $41.78 | -2,252 | 43,316 | -5% | -$94,089 | |||||
| AM | 2018-06-11 | BHVN | Biohaven Pharmaceutical Holding Co Ltd. | Berman Robert | Chief Medical Officer | S - Sale | $36.36 | -76,692 | 244,000 | -24% | -$2,788,707 | |||||
| D | 2018-06-19 | ARWR | Arrowhead Pharmaceuticals, Inc. | Myszkowski Kenneth Allen | CFO | S - Sale+OE | $14.01 | -20,000 | 310,815 | -6% | -$280,200 | |||||
| D | 2018-06-18 | FGEN | Fibrogen Inc | Kurkijarvi Kalevi | Dir | S - Sale+OE | $58.19 | -4,000 | 23,700 | -14% | -$232,760 | |||||
| M | 2018-06-15 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres,COB, CEO, 10% | P - Purchase | $0.27 | +3,000 | 5,509,741 | 0% | +$800 | |||||
| D | 2018-06-18 | CHMA | Chiasma, Inc | Mamluk Roni | Dir | S - Sale+OE | $1.46 | -2,389 | 0 | -100% | -$3,484 | |||||
2018-06-19 | AXSM | Axsome Therapeutics, Inc. | Pizzie Nick | CFO | P - Purchase | $3.10 | +31,000 | 31,000 | New | +$96,080 | ||||||
2018-06-19 | TYME | Tyme Technologies, Inc. | Demurjian Michael | COO, 10% | S - Sale | $3.75 | -18,099 | 26,651,655 | 0% | -$67,871 | ||||||
| D | 2018-06-18 | VTVT | Vtv Therapeutics Inc. | Perelman Ronald O | 10% | P - Purchase | $4.38 | +570,776 | 3,757,218 | +18% | +$2,499,999 | |||||
| M | 2018-06-18 | XNCR | Xencor Inc | Stafford John S III | 10% | S - Sale | $39.90 | -250,000 | 5,261,348 | -5% | -$9,974,392 | |||||
2018-06-18 | TYME | Tyme Technologies, Inc. | Hoffman Steve | CEO, 10% | S - Sale | $3.75 | -13,425 | 26,644,528 | 0% | -$50,344 | ||||||
| M | 2018-06-14 | GALT | Galectin Therapeutics Inc | Czirr James C | Dir | S - Sale | $8.61 | -151,860 | 2,649,786 | -5% | -$1,306,807 | |||||
| M | 2018-06-14 | GALT | Galectin Therapeutics Inc | 10X Fund, L.P. | 10% | S - Sale | $8.61 | -151,860 | 2,649,786 | -5% | -$1,306,807 | |||||
2018-06-19 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $4.32 | +20,000 | 191,339,606 | 0% | +$86,300 | ||||||
2018-06-15 | ABBV | Abbvie Inc. | Richmond Timothy J. | SVP, HR | S - Sale | $99.47 | -17,588 | 0 | -100% | -$1,749,485 | ||||||
| D | 2018-06-18 | SUPN | Supernus Pharmaceuticals Inc | Schwabe Stefan K.F. | EVP R, D, CMO | S - Sale+OE | $54.39 | -60,000 | 1,967 | -97% | -$3,263,352 | |||||
| D | 2018-06-19 | ATHX | Athersys, Inc / New | Lehmann William Jr | Pres, COO | S - Sale+OE | $2.25 | -30,000 | 526,684 | -5% | -$67,380 | |||||
| M | 2018-06-15 | ALRN | Aileron Therapeutics Inc | Apple Tree Partners II LP | 10% | S - Sale | $5.32 | -9,532 | 1,493,145 | -1% | -$50,743 | |||||
| M | 2018-06-13 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres,COB, CEO, 10% | P - Purchase | $0.27 | +2,000 | 5,506,741 | 0% | +$540 | |||||
| D | 2018-06-18 | ENTA | Enanta Pharmaceuticals Inc | Adda Nathalie | SVP, Chief Medical Officer | S - Sale+OE | $114.86 | -4,155 | 3,600 | -54% | -$477,222 | |||||
2018-06-15 | VSAR | Versartis, Inc. | Westberg Paul | SVP, Chief Business Officer | S - Sale | $2.30 | -612 | 225,124 | 0% | -$1,408 | ||||||
2018-06-15 | VSAR | Versartis, Inc. | Haas Kevin | VP, Finance, PAO | S - Sale | $2.30 | -143 | 78,075 | 0% | -$329 | ||||||
| D | 2018-06-15 | BHVN | Biohaven Pharmaceutical Holding Co Ltd. | Gentile Kimberly | VP of Operations | S - Sale+OE | $40.02 | -12,500 | 0 | -100% | -$500,250 | |||||
2018-06-15 | JAZZ | Jazz Pharmaceuticals Plc | Young Matthew P. | EVP, CFO | S - Sale | $176.99 | -700 | 35,568 | -2% | -$123,893 | ||||||
2018-06-15 | NATR | Natures Sunshine Products Inc | Wynnefield Partners Small Cap Value LP | 10% | P - Purchase | $8.96 | +4,010 | 2,202,454 | 0% | +$35,918 | ||||||
2018-06-18 | KERX | Keryx Biopharmaceuticals Inc | Cameron Kevin J | Dir | S - Sale | $4.98 | -1,667 | 176,666 | -1% | -$8,302 | ||||||
| D | 2018-06-18 | KPTI | Karyopharm Therapeutics Inc. | Shacham Sharon | Pres, CSO | S - Sale+OE | $18.66 | -10,000 | 1,320,271 | -1% | -$186,558 | |||||
| D | 2018-06-18 | KPTI | Karyopharm Therapeutics Inc. | Kauffman Michael | CEO | S - Sale+OE | $18.66 | -10,000 | 1,320,271 | -1% | -$186,558 | |||||
| M | 2018-06-13 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.04 | +8,000 | 25,163,289 | 0% | +$300 | |||||
| D | 2018-06-18 | MRK | Merck & Co., Inc. | Schechter Adam H | EVP, Pres-Global Human Health | S - Sale+OE | $61.00 | -134,094 | 62,766 | -68% | -$8,179,945 | |||||
2018-06-18 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $4.34 | +14,299 | 191,319,606 | 0% | +$62,013 | ||||||
2018-06-15 | BMRN | Biomarin Pharmaceutical Inc | Mueller Brian | SVP, Corporate Controller | S - Sale | $94.50 | -2,021 | 13,029 | -13% | -$190,985 | ||||||
| D | 2018-06-14 | BMRN | Biomarin Pharmaceutical Inc | Fuchs Henry J | Pres, Worldwide R, D | S - Sale+OE | $90.00 | -31,000 | 155,167 | -17% | -$2,790,085 | |||||
| DM | 2018-06-14 | ATHX | Athersys, Inc / New | Harrington John J | Exec Vice Pres, CSO | S - Sale+OE | $2.30 | -15,000 | 691,820 | -2% | -$34,513 | |||||
| M | 2018-06-14 | LXRX | Lexicon Pharmaceuticals, Inc. | Invus Public Equities, L.P. | Dir, 10% | P - Purchase | $12.98 | +45,784 | 59,731,328 | 0% | +$594,399 | |||||
| DM | 2018-06-14 | LOXO | Loxo Oncology, Inc. | Kunkel Lori Anne | Dir | S - Sale+OE | $179.83 | -39,232 | 0 | -100% | -$7,055,254 | |||||
2018-06-15 | MCRB | Seres Therapeutics, Inc. | Aunins John G. | CTO, EVP | S - Sale | $8.57 | -14,279 | 170,206 | -8% | -$122,325 | ||||||
2018-06-14 | JAZZ | Jazz Pharmaceuticals Plc | Miller Michael Patrick | EVP, US Commercial | S - Sale | $176.53 | -200 | 25,972 | -1% | -$35,306 | ||||||
2018-06-14 | TGTX | Tg Therapeutics, Inc. | Kennedy William James | Dir | S - Sale | $13.45 | -25,071 | 60,330 | -29% | -$337,205 | ||||||
2018-06-18 | DERM | Dermira, Inc. | Wiggans Thomas G | CEO, COB | P - Purchase | $10.10 | +11,875 | 172,760 | +7% | +$119,954 | ||||||
| D | 2018-06-14 | AGIO | Agios Pharmaceuticals Inc | Foster-Cheek Kaye I | Dir | S - Sale+OE | $93.55 | -9,000 | 2,200 | -80% | -$841,926 | |||||
2018-06-15 | LLY | Lilly Eli & Co | Lilly Endowment Inc | 10% | S - Sale | $86.65 | -180,000 | 122,050,804 | 0% | -$15,597,720 | ||||||
| D | 2018-06-15 | GTHX | G1 Therapeutics, Inc. | Malik Rajesh | Ch. Medical Officer, SVP R, D | S - Sale+OE | $44.31 | -3,776 | 8,400 | -31% | -$167,326 | |||||
2018-06-15 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $4.42 | +10,000 | 191,305,307 | 0% | +$44,200 | ||||||
2018-06-13 | VSAR | Versartis, Inc. | Akkaraju Srinivas | Dir | P - Purchase | $2.13 | +53,018 | 2,682,554 | +2% | +$112,928 | ||||||
| D | 2018-06-15 | XNCR | Xencor Inc | Dahiyat Bassil I | Pres, CEO | S - Sale+OE | $40.51 | -50,000 | 343,067 | -13% | -$2,025,690 | |||||
| D | 2018-06-15 | RARE | Ultragenyx Pharmaceutical Inc. | Huizenga Theodore Alan | VP, Controller, PAO | S - Sale+OE | $83.70 | -955 | 11,940 | -7% | -$79,934 | |||||
| DM | 2018-06-12 | PKTX | Protokinetix, Inc. | Smith Clarence Edward | Pres, CEO, 10% | P - Purchase | $0.10 | +448,500 | 62,579,542 | +1% | +$43,510 | |||||
2018-06-15 | ATNM | Actinium Pharmaceuticals, Inc. | O'Loughlin Steve | Principal Financial Officer | P - Purchase | $0.50 | +12,000 | 25,500 | +89% | +$6,000 | ||||||
| D | 2018-06-13 | XNCR | Xencor Inc | Kuch John J | SVP, CFO | S - Sale+OE | $41.64 | -25,000 | 92,482 | -21% | -$1,040,945 | |||||
2017-11-17 | MYOV | Myovant Sciences Ltd. | Altmeyer Mark | Dir | P - Purchase | $13.38 | +3,500 | 3,500 | New | +$46,830 | ||||||
2018-06-14 | FGEN | Fibrogen Inc | Yu K Peony | Chief Medical Officer | S - Sale | $59.20 | -3,422 | 147,469 | -2% | -$202,582 | ||||||
| DM | 2018-06-13 | FGEN | Fibrogen Inc | Cotroneo Pat | SVP, Finance, CFO | S - Sale+OE | $59.47 | -10,069 | 224,704 | -4% | -$598,806 | |||||
2018-06-14 | EOLS | Evolus, Inc. | Malik Vikram | Dir | P - Purchase | $28.88 | +8,600 | 8,600 | New | +$248,353 | ||||||
| D | 2018-06-13 | ARRY | Array Biopharma Inc | Sandor Victor | Chief Medical Officer | S - Sale+OE | $18.75 | -22,424 | 210,086 | -10% | -$420,450 | |||||
| D | 2018-06-13 | GALT | Galectin Therapeutics Inc | Traber Peter G | Pres, CEO | S - Sale+OE | $7.51 | -100,000 | 107,333 | -48% | -$751,000 | |||||
| D | 2018-06-14 | LCI | Lannett Co Inc | Smith Kevin | SVP of Sales | S - Sale+OE | $16.51 | -11,667 | 18,458 | -39% | -$192,622 | |||||
2018-06-14 | LLY | Lilly Eli & Co | Lilly Endowment Inc | 10% | S - Sale | $86.31 | -107,698 | 122,230,804 | 0% | -$9,295,414 | ||||||
2018-06-14 | TNXP | Tonix Pharmaceuticals Holding Corp. | Sullivan Gregory M | Chief Medical Officer | P - Purchase | $3.96 | +10,000 | 20,482 | +95% | +$39,650 | ||||||
| M | 2018-06-12 | ALBO | Albireo Pharma, Inc. | Mattsson Jan | COO | S - Sale | $32.26 | -25,000 | 34,214 | -42% | -$806,509 | |||||
2018-06-13 | GALT | Galectin Therapeutics Inc | 10X Fund, L.P. | 10% | S - Sale | $7.17 | -208,140 | 2,801,646 | -7% | -$1,493,276 | ||||||
| A | 2018-06-08 | GALT | Galectin Therapeutics Inc | Czirr James C | Dir | S - Sale | $5.88 | -110,000 | 3,009,786 | -4% | -$646,800 | |||||
2018-06-13 | GALT | Galectin Therapeutics Inc | Czirr James C | Dir | S - Sale | $7.17 | -208,140 | 2,801,646 | -7% | -$1,493,276 | ||||||
| D | 2018-05-16 | SNBP | Sun Biopharma, Inc. | Kaysen David B | Pres, CEO | P - Purchase | $0.00 | +1,000 | 51,000 | +2% | +$0 | |||||
| D | 2018-05-16 | SNBP | Sun Biopharma, Inc. | Schaffer Paul W. | Dir | P - Purchase | $0.00 | +5,000 | 1,100,052 | 0% | +$0 | |||||
2018-06-12 | ALRN | Aileron Therapeutics Inc | Apple Tree Partners II LP | 10% | S - Sale | $5.40 | -10,843 | 1,502,677 | -1% | -$58,558 | ||||||
| D | 2018-06-12 | GALT | Galectin Therapeutics Inc | Callicutt Jack W | CFO | S - Sale+OE | $7.01 | -9,294 | 1,260 | -88% | -$65,167 | |||||
| DM | 2018-06-12 | GALT | Galectin Therapeutics Inc | Shlevin Harold H. | COO | S - Sale+OE | $7.41 | -43,698 | 0 | -100% | -$323,986 | |||||
| D | 2018-06-12 | AGIO | Agios Pharmaceuticals Inc | Bowden Christopher | Chief Medical Officer | S - Sale+OE | $92.89 | -2,000 | 881 | -69% | -$185,786 | |||||
| D | 2018-06-12 | TSRO | Tesaro, Inc. | Alleva Lawrence M | Dir | S - Sale+OE | $43.11 | -7,142 | 29,902 | -19% | -$307,920 | |||||
2018-06-14 | LLY | Lilly Eli & Co | Skovronsky Daniel | SVP, CSO,, Pres LRL | P - Purchase | $86.22 | +10,000 | 55,199 | +22% | +$862,200 | ||||||
2018-06-13 | AIMT | Aimmune Therapeutics, Inc. | Bjerkholt Eric | CFO | P - Purchase | $30.41 | +1,600 | 19,485 | +9% | +$48,663 | ||||||
2018-06-12 | TNXP | Tonix Pharmaceuticals Holding Corp. | Lederman Seth | CEO | P - Purchase | $4.37 | +3,000 | 120,393 | +3% | +$13,110 | ||||||
2018-06-14 | TNXP | Tonix Pharmaceuticals Holding Corp. | Saenger Bradley | CFO | P - Purchase | $4.10 | +300 | 3,079 | +11% | +$1,230 | ||||||
2018-06-14 | TNXP | Tonix Pharmaceuticals Holding Corp. | Morris Jessica Edgar | COO | P - Purchase | $4.19 | +300 | 1,638 | +22% | +$1,257 | ||||||
| M | 2018-06-06 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.04 | +8,000 | 25,155,289 | 0% | +$306 | |||||
2018-06-13 | LLY | Lilly Eli & Co | Lilly Endowment Inc | 10% | S - Sale | $86.27 | -11,104 | 122,338,502 | 0% | -$957,953 | ||||||
2018-06-12 | CMRX | Chimerix Inc | Berrey M Michelle | Pres, CEO | P - Purchase | $4.50 | +10,000 | 424,941 | +2% | +$45,015 | ||||||
| DM | 2018-06-11 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $46.44 | -30,000 | 30,000 | -50% | -$1,393,200 | |||||
| DM | 2018-06-11 | PAHC | Phibro Animal Health Corp | Bfi Co., LLC | 10% | S - Sale+OE | $46.44 | -30,000 | 30,000 | -50% | -$1,393,200 | |||||
| D | 2018-06-12 | ZGNX | Zogenix, Inc. | Farfel Gail M | EVP, Chief Development Officer | S - Sale+OE | $45.00 | -5,118 | 7,143 | -42% | -$230,310 | |||||
2018-06-12 | ALKS | Alkermes Plc. | Frates James M | SVP, Alks Inc; CFO ALKS | S - Sale | $50.00 | -16,842 | 183,438 | -8% | -$842,179 | ||||||
2018-06-11 | BMRN | Biomarin Pharmaceutical Inc | Ajer Jeffrey Robert | EVP, Chief Commercial Officer | S - Sale | $90.31 | -1,436 | 50,135 | -3% | -$129,685 | ||||||
2018-06-13 | RARE | Ultragenyx Pharmaceutical Inc. | Huizenga Theodore Alan | VP, Controller, PAO | S - Sale | $76.97 | -1,338 | 9,940 | -12% | -$102,986 | ||||||
2018-06-11 | AKAO | Achaogen Inc | Schilke Tobin | CFO | S - Sale | $11.95 | -2,087 | 47,186 | -4% | -$24,940 | ||||||
2018-06-12 | COLL | Collegium Pharmaceutical, Inc | Fleming Alison B | CTO | S - Sale | $27.00 | -4,096 | 53,362 | -7% | -$110,592 |
Real-time CSV? Options? Alerts? Contact us!
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |